ERBB2 and cancer: Univariate subgroup analysis showed that this signature predicted DMFS in the basal (LogRank P = 0.047) and HER2-positive cancer cohorts (LogRank P = 0.004), though not luminal A or B, or normal-like cancer subgroups (Additional file 9: Figure S6).